KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
This PHASE3 trial investigates Advanced Pancreatic Ductal Adenocarcinoma and is currently ongoing. Jiangsu Alphamab Biopharmaceuticals Co., Ltd leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Dec 2022 — Jul 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Changzhou, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Guiyang, China , Hangzhou, China and 23 more locations